EGFR and neoplasm: We compared these agents to the tyrosine kinase inhibitor erlotinib or to dox withdrawal, which both induce rapid tumor regression by inhibiting EGFR phosphorylation and turning off oncogenic EGFRL858R, respectively (Politi et al., 2006).